Home LiteratureArticle Details
PMID: 18004964 Published · ppublish English Comment Journal Article Review

Optic pathway gliomas: a review.

Neurosurgical focus ·Vol. 23 ·No. 5 ·2007-00-00 ·页码 E2

Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML

Abstract

Optic pathway gliomas represent approximately 3-5% of childhood intracranial tumors. They usually occur in children during the first decade of life and are seen in 11-30% of patients with neurofibromatosis Type 1 (NF1). Although these tumors are typically low-grade gliomas, the clinical course and natural history are highly variable, making treatment paradigms difficult. Overall, however, they are often indolent tumors that can be observed over time for progression without initial treatment, especially in patients with NF1. Chemotherapy is the first-line treatment for progressive tumors, and radiation therapy is reserved for patients with progressive disease who are older than 5-7 years. Surgery is reserved for large tumors causing mass effect or hydrocephalus and tumors confined to the orbit or unilateral optic nerve.

MeSH 主题词
Antineoplastic Agents/therapeutic use Child Child, Preschool Diagnostic Imaging/methods Female Glioma/diagnosis,pathology,therapy Humans Male Optic Nerve Neoplasms/diagnosis,pathology,therapy Prognosis Radiotherapy, Adjuvant Visual Acuity
化学物质
Antineoplastic Agents
作者与单位
共 5 位作者,点击展开单位 / ORCID
Binning Mandy J
Department of Neurosurgery, Primary Children's Medical Center, University of Utah School of Medicine, Salt Lake City, Utah 84113, USA.
Liu James K
Kestle John R W
Brockmeyer Douglas L
Walker Marion L
Article Info
Journal
Neurosurgical focus
Abbr.
Neurosurg Focus
ISSN
1092-0684
Published
2007-00-00
页码
E2
Language
English
Country/Region
United States
NLM ID
100896471
勘误 / 撤稿关联
CommentOn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com